Researchers show safer, more targeted way to deliver CRISPR gene therapy

November 11, 2020

Light-activated liposomes could help to deliver CRISPR gene therapy - and the method could prove safer and more direct than current methods.

A multi-institutional team involving biomedical engineers and scientists from UNSW Sydney found that liposomes - commonly used in pharmacology to encapsulate drugs or genes - can be triggered by light to release the payload in a specific site of the body.

The team, which reported the findings today in ACS Applied Materials and Interfaces, demonstrated their results in cell lines and animal models, with more research needed to test and confirm their method in humans.

Up until now, CRISPR gene therapy technology, which uses a guide RNA to seek out faulty gene sequences and a Cas9 protein to cut or replace it with healthy versions, has used viruses loaded with the CRISPR molecules that then move through the body to find the targeted cells.

While the technology has proved revolutionary - only this year the Nobel Chemistry prize was awarded to researchers developing the technology - the use of viruses as the delivery vehicle is less than ideal because of the potential for adverse immune response and toxicity.

LIPSOMES SAFER OPTION

But in the latest research, the team demonstrated how they could use a much more benign vehicle to carry the CRISPR molecules while using a unique way to deliver them solely to the area of the body in need of them.

Lead author Dr Wei Deng says the team used liposomes - spherical nanostructures of fat molecules very similar to cell membrane material - to carry the CRISPR molecules to the target site in the body.

"Liposomes are already well established as an extremely effective drug-delivery system," she says. "These 'bubbles' are relatively simple to prepare, can be filled with appropriate medication and then injected into the body."

Dr Deng says because liposomes are the most common and well-established drug delivery vehicles, they are much safer than using viruses.

"The traditional delivery vehicle of CRISPR is based on viruses, but they create their own problems because it is difficult to predict the reaction of patients to the viruses."

But having found a safer vehicle to deliver the CRISPR cargo, the team was faced with the challenge of how to ensure these gene-splicing molecules found the right target at the right time. The answer, they discovered, was light.

"Unlike the traditional liposome-based delivery systems, our liposomes can be 'turned on' under light illumination," Dr Deng says. "When light is shone onto the liposomes, they can be disrupted at once, immediately releasing the entire payload."

The team found in both cell lines and animal models that when the liposomes are triggered by an LED light, they eject the CRISPR contents which go to work looking for genes of interest. Dr Deng says the light can activate the liposomes up to a centimetre below the surface of the skin.

DEEP TISSUE TREATMENT

But what if the problem area is deep-seated tumour? Dr Deng says future studies will use X-rays to achieve the same effect.

"We fully expect that we will be able to carry out X-ray triggering of CRISPR delivery in deep tissue at depths greater than one centimetre," she says.

"Our past research has already indicated that liposomes can be triggered by X-rays."

Dr Deng says CRISPR technology is offering exciting possibilities in medical research, especially in treatment of cancer.

"Cancer affects millions of people worldwide, yet researchers have been working for decades to find effective treatments.

"Chemotherapy is great at destroying cancer cells, but because it is untargeted, it ends up damaging normal, healthy cells.

"CRISPR technology has created a very promising tool for developing new targeted, gene and cell-based therapies. Its outcomes would largely increase with the desired delivery system, and in this context, our findings may provide such a system."

Looking ahead, Dr Deng said she and her colleagues are interested in carrying out research that shows X-rays can be used to deliver CRISPR gene-splicing molecules for deep cancer treatment.

"By using X-ray instead of light we also need to find a proper animal model that might translate to using this technology for something like breast cancer treatment. So we're looking for collaborators who have this sort of expertise."
-end-


University of New South Wales

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.